Latest & greatest articles for amiodarone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on amiodarone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on amiodarone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for amiodarone

1. Amiodarone

Amiodarone Top results for amiodarone - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for amiodarone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

2. Amiodarone: Wonder Drug or Wonder Why?

Amiodarone: Wonder Drug or Wonder Why? Emergency Medicine > Journal Club > Archive > January 2018 Toggle navigation January 2018 Amiodarone: Wonder Drug or Wonder Why? Vignette Working in TCC can be draining, and on one particularly busy afternoon, you begin to suspect your own sanity. After back-to-back cardiac arrest patients, you wonder if perhaps you should have done something less stressful with your life, like maybe become a lobster boat captain or an ice road trucker. Your first code (...) is a middle-aged female who suffered cardiac arrest while watching Alabama beat Clemson during the Sugar Bowl (yeah...that's right!!!). She was initially noted to be in ventricular fibrillation (VF), and remained so after three rounds of defibrillation. As she arrives in the trauma room, you immediately continue CPR and set up to shock her again. Your attending orders amiodarone, and even though you remember hearing that this may not be very effective, you realize it's not the time to argue. The patient

Washington University Emergency Medicine Journal Club2018

3. In Patients With Cardiac Arrest, Does Amiodarone or Lidocaine Increase Meaningful Survival?

In Patients With Cardiac Arrest, Does Amiodarone or Lidocaine Increase Meaningful Survival? DEFINE_ME_WA This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.

Annals of Emergency Medicine Systematic Review Snapshots2017

4. Amiodarone: A potential risk factor for retinal phototoxicity

Amiodarone: A potential risk factor for retinal phototoxicity 29503963 2018 11 14 2451-9936 5 2017 Apr American journal of ophthalmology case reports Am J Ophthalmol Case Rep Amiodarone: A potential risk factor for retinal phototoxicity. 119-123 10.1016/j.ajoc.2016.12.019 To report the only known case, to our knowledge, of amiodarone induced retinal phototoxicity following vitrectomy surgery. A 66-year-old male presented with visual acuity of 20/150 OS secondary to an epiretinal membrane (ERM (...) ). Patient was on oral amiodarone for atrial fibrillation. Baseline spectral domain optical coherence tomography (SD-OCT) revealed an ERM with retinal thickening and schisis. The patient underwent an uncomplicated pars plana vitrectomy and membrane peel using standard vitrectomy settings and illumination. Triamcinolone was used to stain the ERM intraoperatively. ICG was not used. On post-operative day one, vision was count finger (CF) at 1'. At post-operative week one, vision was unchanged and SD-OCT

American journal of ophthalmology case reports2016 Full Text: Link to full Text with Trip Pro

5. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study

Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study 27354046 2016 06 29 2017 05 18 1522-9645 38 17 2017 May 01 European heart journal Eur. Heart J. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. 1329-1335 10.1093/eurheartj/ehw230 Intravenous procainamide and amiodarone are drugs (...) of choice for well-tolerated ventricular tachycardia. However, the choice between them, even according to Guidelines, is unclear. We performed a multicentre randomized open-labelled study to determine the safety and efficacy of intravenous procainamide and amiodarone for the acute treatment of tolerated wide QRS complex (probably ventricular) tachycardia. Patients were randomly assigned to receive intravenous procainamide (10 mg/kg/20 min) or amiodarone (5 mg/kg/20 min). The primary endpoint

EvidenceUpdates2016

6. EMA recommends avoidance of certain hepatitis C medicines and amiodarone together

EMA recommends avoidance of certain hepatitis C medicines and amiodarone together European Medicines Agency - Human medicines - EMA recommends avoidance of certain hepatitis C medicines and amiodarone together Search for medicines Main navigation Patient safety EMA recommends avoidance of certain hepatitis C medicines and amiodarone together Press release 24/04/2015 EMA recommends avoidance of certain hepatitis C medicines and amiodarone together Concomitant use may increase risk of slow heart (...) rate and related problems The European Medicines Agency (EMA) has confirmed a risk of severe bradycardia (slow heart rate) or heart block (problems with conduction of electrical signals in the heart) when the hepatitis C medicines Harvoni (sofosbuvir with ledipasvir) or a combination of Sovaldi (sofosbuvir) and Daklinza (daclatasvir) are used in patients who are also taking the medicine amiodarone, which is an antiarrhythmic (a medicine used to treat irregular heartbeat). To manage this risk

European Medicines Agency - EPARs2016

7. Amiodarone versus Lidocaine for Arrhythmias: Comparative Clinical Effectiveness

Amiodarone versus Lidocaine for Arrhythmias: Comparative Clinical Effectiveness Amiodarone versus Lidocaine for Arrhythmias: Comparative Clinical Effectiveness | CADTH.ca Find the information you need Amiodarone versus Lidocaine for Arrhythmias: Comparative Clinical Effectiveness Amiodarone versus Lidocaine for Arrhythmias: Comparative Clinical Effectiveness Published on: January 8, 2016 Project Number: RB0949-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type (...) : Report Question What is the comparative clinical effectiveness of intravenous amiodarone versus intravenous lidocaine for patients in cardiac arrest or with life-threatening arrhythmias? Key Message One systematic review, two randomized controlled trials, and one non-randomized study were identified regarding intravenous amiodarone versus intravenous lidocaine for arrhythmias. Tags amiodarone, death, heart arrest, lidocaine, heart attack, Arrhythmias, Cardiac, Cardiac, Sudden Files Rapid Response

Canadian Agency for Drugs and Technologies in Health - Rapid Review2016

8. Amiodarone method of administration for treatment of post-operative atrial fibrillation

Amiodarone method of administration for treatment of post-operative atrial fibrillation Amiodarone method of administration for treatment of post-operative atrial fibrillation Amiodarone method of administration for treatment of post-operative atrial fibrillation Mitchell MD, Strauss R, Mull N. Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Mitchell MD, Strauss R, Mull N.. Amiodarone method of administration for treatment of post-operative atrial fibrillation. Philadelphia: Center for Evidence-based Practice (CEP). 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Postoperative Period Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence

Health Technology Assessment (HTA) Database.2016

9. Amiodarone for prevention of atrial fibrillation in cardiac surgery patients

Amiodarone for prevention of atrial fibrillation in cardiac surgery patients Amiodarone for prevention of atrial fibrillation in cardiac surgery patients Amiodarone for prevention of atrial fibrillation in cardiac surgery patients Mitchell MD, Reynolds CR, Mull N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mitchell MD, Reynolds CR (...) , Mull N. Amiodarone for prevention of atrial fibrillation in cardiac surgery patients. Philadelphia: Center for Evidence-based Practice (CEP). 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Amiodarone; Atrial Fibrillation; Cardiac Surgical Procedures; Humans Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence Center for Evidence-based Practice, University

Health Technology Assessment (HTA) Database.2016

10. Simeprevir with sofosbuvir: risk of severe bradycardia and heart block when taken with amiodarone

Simeprevir with sofosbuvir: risk of severe bradycardia and heart block when taken with amiodarone Simeprevir with sofosbuvir: risk of severe bradycardia and heart block when taken with amiodarone - GOV.UK GOV.UK uses cookies to make the site simpler. Search Simeprevir with sofosbuvir: risk of severe bradycardia and heart block when taken with amiodarone From: Published: 19 August 2015 Therapeutic area: and Avoid concomitant use of amiodarone with simeprevir (Olysio▼) and sofosbuvir (Sovaldi (...) ▼) combination therapy, unless other antiarrhythmics cannot be given. When treating patients with both heart rhythm disorders and hepatitis C: closely monitor patients taking amiodarone if they start taking the combination simeprevir and sofosbuvir; sofosbuvir and daclatasvir; and the fixed-dose combination of sofosbuvir and ledipasvir (particularly during the first weeks of treatment) only start amiodarone in patients taking any of these antiviral combinations when other antiarrhythmics are not tolerated

MHRA Drug Safety Update2015

11. Sofosbuvir with daclatasvir; sofosbuvir and ledipasvir: risks of severe bradycardia and heart block when taken with amiodarone

Sofosbuvir with daclatasvir; sofosbuvir and ledipasvir: risks of severe bradycardia and heart block when taken with amiodarone Sofosbuvir with daclatasvir; sofosbuvir and ledipasvir: risks of severe bradycardia and heart block when taken with amiodarone - GOV.UK GOV.UK uses cookies to make the site simpler. Search Sofosbuvir with daclatasvir; sofosbuvir and ledipasvir: risks of severe bradycardia and heart block when taken with amiodarone From: Published: 20 May 2015 Therapeutic area: and Avoid (...) concomitant use of amiodarone with ledipasvir-sofosbuvir (Harvoni▼), and amiodarone with sofosbuvir (Sovaldi▼) and daclatasvir (Daklinza▼), unless other antiarrhythmics cannot be given. Contents When treating patients with both heart rhythm disorders and hepatitis C: closely monitor patients taking amiodarone if they start taking the fixed-dose combination of sofosbuvir and ledipasvir, or sofosbuvir in combination with daclatasvir (particularly during the first weeks of treatment) only start amiodarone

MHRA Drug Safety Update2015

12. Meta-analysis of amiodarone versus beta-blocker as a prophylactic therapy against atrial fibrillation following cardiac surgery

Meta-analysis of amiodarone versus beta-blocker as a prophylactic therapy against atrial fibrillation following cardiac surgery Meta-analysis of amiodarone versus beta-blocker as a prophylactic therapy against atrial fibrillation following cardiac surgery Meta-analysis of amiodarone versus beta-blocker as a prophylactic therapy against atrial fibrillation following cardiac surgery Zhu J, Wang C, Gao D, Zhang C, Zhang Y, Lu Y, Gao Y CRD summary The authors concluded that amiodarone and beta (...) -blockers seemed to have similar efficacy and safety for reducing the risk of postoperative atrial fibrillation. This appeared to have been a well conducted review and the authors' conclusions reflect the evidence presented, but limitations of the evidence base and mean that these conclusions may not be entirely reliable. Authors' objectives To compare the efficacy of amiodarone and beta-blockers for preventing postoperative atrial fibrillation. Searching MEDLINE, Web of Science and Cochrane Central Register

DARE.2013

13. Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis.

Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis. Amiodarone prophylaxis reduces ma... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 2005 ) Volume: 143 , Issue: 5 , Publisher: Rush University Medical Center, Chicago, Illinois 60612, USA. , Pages: 327-336 PubMed: Available from or Find this paper at: Abstract (...) BACKGROUND: Although evidence supports the prophylactic use of beta-blockade in cardiac surgery, postoperative atrial fibrillation or flutter occurs in 40% to 60% of patients. Trials that assessed whether amiodarone prophylaxis decreases the incidence of postoperative atrial tachyarrhythmias have had mixed results and were not specifically powered to detect changes in cardiovascular morbidity, length of stay, or mortality. PURPOSE: To see whether prophylactic administration of amiodarone decreases

Annals of Internal Medicine2013

14. Amiodarone versus lidocaine and placebo for the prevention of ventricular fibrillation after aortic crossclamping: A randomized, double-blind, placebo-controlled trial

Amiodarone versus lidocaine and placebo for the prevention of ventricular fibrillation after aortic crossclamping: A randomized, double-blind, placebo-controlled trial 22770549 2012 10 19 2013 01 10 2013 11 21 1097-685X 144 5 2012 Nov The Journal of thoracic and cardiovascular surgery J. Thorac. Cardiovasc. Surg. Amiodarone versus lidocaine and placebo for the prevention of ventricular fibrillation after aortic crossclamping: a randomized, double-blind, placebo-controlled trial. 1229-34 10.1016 (...) /j.jtcvs.2012.06.039 S0022-5223(12)00718-0 Ventricular fibrillation occurs commonly after aortic crossclamping in patients undergoing cardiac surgery. Ventricular fibrillation increases myocardial oxygen consumption, and defibrillation may harm the myocardium. Thus, a pharmacologic approach to decreasing the incidence of ventricular fibrillation or the number of shocks required may be beneficial. The goal of this study was to evaluate whether amiodarone or lidocaine was superior to placebo

EvidenceUpdates2012

15. Effectiveness of amiodarone versus bepridil in achieving conversion to sinus rhythm in patients with persistent atrial fibrillation: a randomised trial

Effectiveness of amiodarone versus bepridil in achieving conversion to sinus rhythm in patients with persistent atrial fibrillation: a randomised trial 22689712 2012 06 28 2012 09 04 2013 11 21 1468-201X 98 14 2012 Jul Heart (British Cardiac Society) Heart Effectiveness of amiodarone versus bepridil in achieving conversion to sinus rhythm in patients with persistent atrial fibrillation: a randomised trial. 1067-71 10.1136/heartjnl-2012-302017 Pharmacological conversion to sinus rhythm (...) is generally difficult to achieve, particularly in long-lasting persistent atrial fibrillation (AF). The purpose of this study is to compare the effectiveness of two agents, amiodarone and bepridil, in achieving conversion to sinus rhythm in patients with persistent AF. Amiodarone (A) or bepridil (B) was administered to 40 consecutive patients (36 male subjects, age 61 years) with persistent AF in a prospective, randomised, open label fashion. The pharmacological effects in bringing about conversion

EvidenceUpdates2012

16. Amiodarone Significantly Decreases Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer

Amiodarone Significantly Decreases Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer 22516832 2012 07 23 2012 10 01 2013 11 21 1552-6259 94 2 2012 Aug The Annals of thoracic surgery Ann. Thorac. Surg. Amiodarone significantly decreases atrial fibrillation in patients undergoing surgery for lung cancer. 339-44; discussion 345-6 10.1016/j.athoracsur.2011.12.096 Postoperative atrial fibrillation occurs in 5% to 65% of patients undergoing thoracic surgery. Although postoperative (...) atrial fibrillation often is regarded as a temporary, benign, operation-related problem, it is associated with a twofold to threefold increase in risk of adverse events, including transient or permanent stroke, acute myocardial infarction, and death. A total of 254 consecutively eligible enrolled patients undergoing surgery for lung cancer were included in this randomized, controlled, double-blinded trial. Patients received 300 mg of amiodarone or placebo intravenously over 20 minutes immediately after surgery

EvidenceUpdates2012

17. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation

Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M CRD summary The review (...) concluded that all the included antiarrhythmic drugs were efficacious in delaying recurrence of atrial fibrillation. Amiodarone was the most effective in maintaining sinus rhythm. Sotalol and possibly amiodarone increased mortality. Dronedarone possibly decreased serious adverse events and proarrhythmia. The poor quality of many of the included trials and differences across trials limits the reliability of pooled results. Authors' objectives To assess the relative efficacy and tolerability of the main

DARE.2012

18. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation

A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation 21232669 2011 01 14 2011 02 14 2013 11 21 1558-3597 57 3 2011 Jan 18 Journal of the American College of Cardiology J. Am. Coll. Cardiol. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. 313-21 10.1016/j.jacc.2010.07.046 This randomized double-blind study compared (...) the efficacy and safety of intravenous vernakalant and amiodarone for the acute conversion of recent-onset atrial fibrillation (AF). Intravenous vernakalant has effectively converted recent-onset AF and was well tolerated in placebo-controlled studies. A total of 254 adult patients with AF (3 to 48 h duration) eligible for cardioversion were enrolled in the study. Patients received either a 10-min infusion of vernakalant (3 mg/kg) followed by a 15-min observation period and a second 10-min infusion (2 mg

EvidenceUpdates2011

19. A randomized, controlled study of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy

A randomized, controlled study of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy 20381077 2010 07 12 2010 08 12 2015 11 19 1097-685X 140 1 2010 Jul The Journal of thoracic and cardiovascular surgery J. Thorac. Cardiovasc. Surg. A randomized, controlled study of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy. 45-51 10.1016/j.jtcvs.2010.01.026 Atrial fibrillation is common after esophagectomy. The objective of this study (...) was to determine the efficacy and safety of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy. Eighty patients undergoing transthoracic esophagectomy were randomly, prospectively assigned to receive amiodarone (n = 40) or no prophylaxis (control group, n = 40). Amiodarone-treated patients received the drug by continuous infusion, initiated at the time of induction of anesthesia, at a rate of 0.73 mg/min (43.75 mg/h), and continued for 96 hours (total dose 4200 mg). The primary

EvidenceUpdates2010

20. Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure. Analysis From the Sudden Cardiac Death in Heart Failure Trial

Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure. Analysis From the Sudden Cardiac Death in Heart Failure Trial 19917887 2009 12 01 2010 01 05 2016 12 15 1524-4539 120 22 2009 Dec 01 Circulation Circulation Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. 2170-6 (...) randomized 2521 subjects to placebo, amiodarone, or shock-only, single-lead ICD therapy. Over a median follow-up of 45.5 months, a total of 666 deaths occurred, which were reviewed by an Events Committee and initially categorized as cardiac or noncardiac. Cardiac deaths were further adjudicated as resulting from sudden death presumed to be ventricular tachyarrhythmic, bradyarrhythmia, heart failure, or other cardiac causes. ICD therapy significantly reduced cardiac mortality compared with placebo

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro